The United Kingdom and the United States have agreed to a landmark trade agreement that will guarantee zero duties on British pharmaceutical exports entering the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase expenditure on pharmaceuticals through the NHS. This commitment secures that tariffs on these crucial exports will remain at zero for a timeframe of the next three years.
This development follows previous threats to hike duties on branded pharmaceutical imports, with figures floated as high as 100%.
"This arrangement between the United Kingdom reinforces the global environment for cutting-edge drugs and establishes much-needed fairness to U.S.–U.K. medicine commerce," a release noted.
Commercial Impact
Drugs are one of the UK's most significant exports to the America, which is by far the primary market for major British pharmaceutical firms.
Export figures show that in the one-year period leading up to last September, the UK exported pharmaceutical products valued at £11.1bn to the US. This figure represented a significant portion of British export trade in that timeframe.
"This guarantee safeguards employment, boosts capital expenditure and facilitates the UK to establish itself as a worldwide center for life sciences," a minister remarked.
Detailed UK Commitments
The pact includes several specific pledges from the British government:
- Revised Affordability Limit: The UK will raise the price threshold at which it considers new therapies to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a aim to raise overall NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The amount drug companies must return to the NHS to stay within budget will be restricted at 15%. Previously, refunds exceeded twenty percent.
Industry Background
This agreement comes amid a long-running tension between the pharmaceutical industry and the British authorities over spending levels and regulatory access.
The disagreement were intensified by claims that US consumers were paying several times more for the identical medicines than people in the Britain and the EU.
Recently, several major drug company projects in the UK have been paused or cancelled, while major funding commitments have been pledged toward US facilities.
The Science Minister publicly accepted that the NHS had to increase expenditure on medicines, noting that its budget allocation on drugs had declined as a proportion of its total funding over the past decade.
